Titre : Protéines associées aux CRISPR

Protéines associées aux CRISPR : Questions médicales fréquentes

Termes MeSH sélectionnés :

Gene Expression Profiling
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines associées aux CRISPR : Questions médicales les plus fréquentes", "headline": "Protéines associées aux CRISPR : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines associées aux CRISPR : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-15", "dateModified": "2025-02-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines associées aux CRISPR" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines", "url": "https://questionsmedicales.fr/mesh/D011506", "about": { "@type": "MedicalCondition", "name": "Protéines", "code": { "@type": "MedicalCode", "code": "D011506", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Protéine-9 associée à CRISPR", "alternateName": "CRISPR-Associated Protein 9", "url": "https://questionsmedicales.fr/mesh/D000076987", "about": { "@type": "MedicalCondition", "name": "Protéine-9 associée à CRISPR", "code": { "@type": "MedicalCode", "code": "D000076987", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.212.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Protéines associées aux CRISPR", "alternateName": "CRISPR-Associated Proteins", "code": { "@type": "MedicalCode", "code": "D064130", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yi Zhang", "url": "https://questionsmedicales.fr/author/Yi%20Zhang", "affiliation": { "@type": "Organization", "name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China." } }, { "@type": "Person", "name": "Yue Feng", "url": "https://questionsmedicales.fr/author/Yue%20Feng", "affiliation": { "@type": "Organization", "name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. Electronic address: fengyue@mail.buct.edu.cn." } }, { "@type": "Person", "name": "Joseph Bondy-Denomy", "url": "https://questionsmedicales.fr/author/Joseph%20Bondy-Denomy", "affiliation": { "@type": "Organization", "name": "Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94143, USA." } }, { "@type": "Person", "name": "Alan R Davidson", "url": "https://questionsmedicales.fr/author/Alan%20R%20Davidson", "affiliation": { "@type": "Organization", "name": "Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: alan.davidson@utoronto.ca." } }, { "@type": "Person", "name": "Xu Peng", "url": "https://questionsmedicales.fr/author/Xu%20Peng", "affiliation": { "@type": "Organization", "name": "Department of Biology, University of Copenhagen, Copenhagen N, Denmark. Electronic address: peng@bio.ku.dk." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Genome-wide identification and expression profiling of sugar transporter genes in tobacco.", "datePublished": "2022-06-14", "url": "https://questionsmedicales.fr/article/35714802", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.gene.2022.146652" } }, { "@type": "ScholarlyArticle", "name": "Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy.", "datePublished": "2023-08-02", "url": "https://questionsmedicales.fr/article/37533202", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cam4.6411" } }, { "@type": "ScholarlyArticle", "name": "The NeuroinflammatoryPotential of HIV-1 NefVariants in Modulating the Gene Expression Profile of Astrocytes.", "datePublished": "2022-10-17", "url": "https://questionsmedicales.fr/article/36291123", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cells11203256" } }, { "@type": "ScholarlyArticle", "name": "Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression.", "datePublished": "2022-06-30", "url": "https://questionsmedicales.fr/article/35771282", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00401-022-02460-1" } }, { "@type": "ScholarlyArticle", "name": "Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies.", "datePublished": "2024-09-24", "url": "https://questionsmedicales.fr/article/39317454", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/rmdopen-2024-004600" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines associées aux CRISPR", "item": "https://questionsmedicales.fr/mesh/D064130" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines associées aux CRISPR - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines associées aux CRISPR", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protéines associées aux CRISPR", "description": "Comment identifier les protéines CRISPR dans un échantillon ?\nQuels tests sont utilisés pour détecter les protéines associées ?\nPeut-on détecter les protéines CRISPR par imagerie ?\nQuels marqueurs sont spécifiques aux protéines CRISPR ?\nComment évaluer l'activité des protéines CRISPR ?", "url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Gene+Expression+Profiling&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protéines associées aux CRISPR", "description": "Quels symptômes sont liés à des dysfonctionnements CRISPR ?\nLes protéines CRISPR causent-elles des effets secondaires ?\nComment les protéines CRISPR affectent-elles la santé ?\nY a-t-il des symptômes d'allergie aux protéines CRISPR ?\nLes protéines CRISPR peuvent-elles provoquer des cancers ?", "url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Gene+Expression+Profiling&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protéines associées aux CRISPR", "description": "Comment prévenir les maladies liées aux protéines CRISPR ?\nLes vaccins peuvent-ils intégrer CRISPR ?\nY a-t-il des mesures préventives pour les traitements CRISPR ?\nComment éduquer sur les risques des CRISPR ?\nLes tests génétiques peuvent-ils prévenir des maladies ?", "url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Gene+Expression+Profiling&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protéines associées aux CRISPR", "description": "Comment les protéines CRISPR sont-elles utilisées en thérapie ?\nQuels types de maladies peuvent être traités avec CRISPR ?\nY a-t-il des traitements en cours avec CRISPR ?\nQuels sont les défis des traitements CRISPR ?\nCRISPR peut-il être utilisé pour des maladies infectieuses ?", "url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Gene+Expression+Profiling&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protéines associées aux CRISPR", "description": "Quelles complications peuvent survenir avec CRISPR ?\nComment gérer les complications des traitements CRISPR ?\nLes complications sont-elles fréquentes avec CRISPR ?\nQuelles sont les conséquences des effets hors cible ?\nLes complications peuvent-elles être réversibles ?", "url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Gene+Expression+Profiling&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protéines associées aux CRISPR", "description": "Quels sont les facteurs de risque pour les traitements CRISPR ?\nLes mutations génétiques augmentent-elles les risques ?\nL'environnement influence-t-il les risques liés à CRISPR ?\nLes antécédents familiaux sont-ils un facteur de risque ?\nLes traitements antérieurs affectent-ils les risques ?", "url": "https://questionsmedicales.fr/mesh/D064130?mesh_terms=Gene+Expression+Profiling&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les protéines CRISPR dans un échantillon ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par des techniques comme la PCR et le séquençage." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les protéines associées ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'immunobuvardage et de chromatographie peuvent être utilisés." } }, { "@type": "Question", "name": "Peut-on détecter les protéines CRISPR par imagerie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des techniques comme la microscopie à fluorescence peuvent être utilisées." } }, { "@type": "Question", "name": "Quels marqueurs sont spécifiques aux protéines CRISPR ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs spécifiques incluent les séquences génétiques uniques des gènes cas." } }, { "@type": "Question", "name": "Comment évaluer l'activité des protéines CRISPR ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'activité peut être évaluée par des tests de coupure d'ADN et d'édition génétique." } }, { "@type": "Question", "name": "Quels symptômes sont liés à des dysfonctionnements CRISPR ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes peuvent inclure des anomalies génétiques et des maladies héréditaires." } }, { "@type": "Question", "name": "Les protéines CRISPR causent-elles des effets secondaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires peuvent survenir, comme des réponses immunitaires indésirables." } }, { "@type": "Question", "name": "Comment les protéines CRISPR affectent-elles la santé ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent influencer la santé en modifiant des gènes liés à des maladies." } }, { "@type": "Question", "name": "Y a-t-il des symptômes d'allergie aux protéines CRISPR ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des réactions allergiques peuvent survenir, mais elles sont rares et peu documentées." } }, { "@type": "Question", "name": "Les protéines CRISPR peuvent-elles provoquer des cancers ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des modifications génétiques inappropriées peuvent augmenter le risque de cancer." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux protéines CRISPR ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par des dépistages génétiques et des conseils en génétique." } }, { "@type": "Question", "name": "Les vaccins peuvent-ils intégrer CRISPR ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches explorent l'utilisation de CRISPR pour améliorer les vaccins existants." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour les traitements CRISPR ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures incluent le suivi des effets secondaires et l'évaluation des risques." } }, { "@type": "Question", "name": "Comment éduquer sur les risques des CRISPR ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation passe par des campagnes d'information et des ressources en santé publique." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils prévenir des maladies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques permettent d'identifier les risques et de prendre des mesures." } }, { "@type": "Question", "name": "Comment les protéines CRISPR sont-elles utilisées en thérapie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont utilisées pour corriger des mutations génétiques dans des thérapies géniques." } }, { "@type": "Question", "name": "Quels types de maladies peuvent être traités avec CRISPR ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "CRISPR peut traiter des maladies génétiques, des cancers et des infections virales." } }, { "@type": "Question", "name": "Y a-t-il des traitements en cours avec CRISPR ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs essais cliniques explorent l'utilisation de CRISPR pour diverses maladies." } }, { "@type": "Question", "name": "Quels sont les défis des traitements CRISPR ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les défis incluent la précision de l'édition et les effets hors cible potentiels." } }, { "@type": "Question", "name": "CRISPR peut-il être utilisé pour des maladies infectieuses ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, CRISPR est exploré pour cibler et éliminer des virus dans des infections." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec CRISPR ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des modifications hors cible et des réactions immunitaires." } }, { "@type": "Question", "name": "Comment gérer les complications des traitements CRISPR ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi médical rigoureux et des ajustements de traitement." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes avec CRISPR ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont rares mais peuvent survenir, nécessitant une surveillance." } }, { "@type": "Question", "name": "Quelles sont les conséquences des effets hors cible ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les effets hors cible peuvent entraîner des mutations indésirables et des maladies." } }, { "@type": "Question", "name": "Les complications peuvent-elles être réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles, mais cela dépend du cas spécifique." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les traitements CRISPR ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, l'état de santé et les antécédents médicaux." } }, { "@type": "Question", "name": "Les mutations génétiques augmentent-elles les risques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines mutations peuvent accroître le risque de complications avec CRISPR." } }, { "@type": "Question", "name": "L'environnement influence-t-il les risques liés à CRISPR ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'environnement peut jouer un rôle dans l'expression des gènes modifiés." } }, { "@type": "Question", "name": "Les antécédents familiaux sont-ils un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies génétiques peuvent augmenter les risques." } }, { "@type": "Question", "name": "Les traitements antérieurs affectent-ils les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements antérieurs peuvent influencer la réponse aux thérapies CRISPR." } } ] } ] }

Sources (10000 au total)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy.

Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Chemotherapy is the mainstay systemic therapy for PDAC, and chemoresistance is a major clinical problem leadi... Archived formalin-fixed paraffin-embedded tumor tissue samples from patients treated with neoadjuvant chemotherapy were obtained during surgical resection. Specimens were macrodissected and gene expre... Initially, unsupervised multivariate modeling was performed by principal component analysis, which demonstrated a distinct gene expression profile between good- and poor-chemotherapy responders. There... A distinct tumor biological profile between PDAC patients who either respond or not respond to chemotherapy was identified....

Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies.

To identify differentially expressed genes in temporal artery biopsies (TABs) from patients with giant cell arteritis (GCA) with different histological patterns of inflammation: transmural inflammatio... Expression of 770 immune-related genes was profiled with the NanoString nCounter PanCancer Immune Profiling Panel on formalin-fixed paraffin-embedded TABs from 42 GCA patients with TMI, 7 GCA patients... Unsupervised clustering of the samples revealed two distinct groups: normal TABs and TABs with ILA in one group, 41/42 TABs with TMI in the other one. TABs with TMI showed 31 downregulated and 256 upr... TABs with TMI had a distinct transcriptome compared with normal TABs and TABs with ILA. The few genes potentially deregulated in ILA were also deregulated in TMI. Gene profiling allowed to deepen the ...

Identification and Validation of Common Reference Genes for Normalization of Esophageal Squamous Cell Carcinoma Gene Expression Profiles.

Esophageal squamous cell carcinoma (ESCC) is one of the subtypes of esophageal cancer with Chinese characteristics, and its five-year survival rate is less than 20%. Early diagnosis is beneficial to i...

Identification and Validation of Autophagy-Related Genes in Primary Ovarian Insufficiency by Gene Expression Profile and Bioinformatic Analysis.

To investigate the relationship between primary ovarian insufficiency and autophagy, we detected and got the expression profile of human granulosa cell line SVOG, which was with or without LPS induced... Totally, 6 genes were selected as candidate hub genes which might correlate with the process of primary ovarian insufficiency. The expression of hub genes was then validated by quantitative real-time ... The results indicated that autophagy might play an essential role in the process and underlying molecular mechanism of primary ovarian insufficiency, which was revealed for the first time and may help...

Intralesional gene expression profile of JAK-STAT signaling pathway and associated cytokines in

The JAK-STAT signaling pathway is a central cascade of signal transduction for the myriad of cytokines in which dysregulation has been implicated in progression of inflammatory and infectious diseases... This study sought to investigate differential gene expression of several cytokines and their associated... Results showed that the gene expression levelsof both Th1 (... Our finding revealed dysregulation of cytokines and related...

Identification and gene expression profiling of human gonadotrophic pituitary adenoma stem cells.

Gonadotrophic pituitary adenoma is a major subtype of pituitary adenoma in the sellar region, but it is rarely involved in the hypersecretion of hormones into blood; thus, it is commonly regarded as "... The hPASCs from 14 human gonadotrophic pituitary adenoma clinical samples were cultured and verified via immunohistochemistry. Genetic profiling of hPASCs and the matched tumor cells was performed thr... The hPASCs were successfully isolated and cultured from gonadotrophic pituitary adenoma in vitro, which were identified as positive for generic stem cell markers (Sox2, Oct4, Nestin and CD133) via imm... Genetic profiling of hPASCs may explain the tumorigenesis and invasiveness of gonadotrophic pituitary adenoma. ANXA2 may serve as a potential therapeutic target for the treatment of gonadotrophic pitu...